Brief: Liminal BioSciences Provides Update On Progress On BLA For Ryplazim

Liminal BioSciences

21/09/2020 14:18

Sept 21 (Reuters) - Liminal BioSciences Inc  LMNL.O :
    * LIMINAL BIOSCIENCES PROVIDES UPDATE ON PROGRESS ON BLA FOR
RYPLAZIM®(PLASMINOGEN)
    * LIMINAL BIOSCIENCES - FDA CONFIRMED THAT RESUBMISSION IS A
COMPLETE, CLASS 2 RESPONSE AND HAS PROVIDED A PDUFA TARGET
ACTION DATE OF MARCH 5, 2021
    * LIMINAL BIOSCIENCES - FDA ACKNOWLEDGED RECEIPT OF
RESUBMISSION,
BY ITS U.S. SUBSIDIARY, PROMETIC BIOTHERAPEUTICS INC., OF BLA
FOR RYPLAZIM
    * LIMINAL BIOSCIENCES - SEES POTENTIAL APPROVAL AND
COMMERCIAL
LAUNCH OF RYPLAZIM IN U.S. IN 2021

Source text for Eikon:  ID:nCNWB3qkJa 
Further company coverage:  LMNL.O 

 ((Reuters.Briefs@thomsonreuters.com;))